Attached files
file | filename |
---|---|
8-K - RESPONSE GENETICS INC | v210248_8k.htm |
Exhibit
99.1
FOR
IMMEDIATE RELEASE
Investor
Relations Contact:
|
Media
Relations Contact:
|
Peter
Rahmer
|
Barry
Sudbeck
|
Trout
Group
|
Fleishman-Hillard
|
646-378-2973
|
415-318-4261
|
Response
Genetics, Inc. Announces Appointment of Company President
LOS ANGELES, February 7, 2011
— Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development
and commercialization of molecular diagnostic tests for cancer, announced today
the addition of Christine Meda as the Company’s president. Kathleen Danenberg,
who held this position previously, will continue to act as chief executive
officer of the Company. In her role, Ms. Meda will be responsible for helping in
the execution of the Company’s strategy and operations on a day-to-day basis
and, with her unique expertise in cancer diagnostics, leading the Company in new
areas of the market, such as the development of companion
diagnostics.
“With her
strong background in the diagnostics industry, Christine’s strategic vision and
considerable business experience have helped companies successfully develop,
launch and market products,” said Ms. Danenberg, CEO. “And with our
current growth rate in the double digits, her addition to the senior management
team will help Response Genetics expand its market and realize its growth
potential.”
Ms. Meda
brings nearly 30 years of experience in strategic partnering, operations and
marketing to her role at Response Genetics. Most recently, Ms. Meda was
president and chief executive officer of Arcxis Biotechnologies, an early-stage
molecular diagnostics company. Ms. Meda also founded and is president of
RxDxLink, a consulting service company to early state and small biotechnology
companies. She served as president and chief operating officer for
Diamics, Inc., an early-stage cancer diagnostics company, and over a four year
period before that, she held various positions of increasing importance at Roche
Molecular Diagnostics, including vice president of Business Development and vice
president of Women’s Health, where she had portfolio responsibility bringing
five molecular diagnostics through the pipeline to market. Ms. Meda received a
Bachelor of Science degree in the State University of New York at
Potsdam.
Ms. Meda,
commenting on her appointment said, “I am pleased to be joining Response
Genetics, a company with a unique platform technology and differentiated product
offering. I look forward to applying my skills and experience knowing that I am
not only providing value to the company and its shareholders, but helping
improve the diagnostic information used to treat people with
cancer.”
–
more –
About
Response Genetics, Inc.
Response
Genetics Inc. (“RGI”) is focused on the development and sale of molecular
diagnostic tests for cancer. RGI’s technologies enable extraction and analysis
of genetic information from genes derived from tumor samples stored as
formalin-fixed and paraffin-embedded specimens. In addition to diagnostic
testing services, the Company generates revenue from the sales of its
proprietary analytical pharmacogenomic testing services of clinical trial
specimens to the pharmaceutical industry. RGI was founded in 1999 and its
principal headquarters are located in Los Angeles, California. For more
information, please visit www.responsegenetics.com.
Forward-Looking
Statement Notice
Except
for the historical information contained herein, this press release and the
statements of representatives of RGI related thereto contain or may contain,
among other things, certain forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements
involve significant risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company’s plans, objectives,
projections, expectations and intentions, such as the ability of the
Company to enter into
new areas such as companion diagnostics, and to continue to execute on its
business strategy and operations, to continue to analyze cancer samples, the
potential for using the results of this research to develop diagnostic tests for
cancer, the usefulness of genetic information to tailor treatment to patients,
the usefulness of gene
profiling as a predictor of response to chemotherapy in gastrointestinal
cancers, and other statements identified by
words such as “projects,” “may,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans” or similar
expressions.
These
statements are based upon the current beliefs and expectations of the Company’s
management and are subject to significant risks and uncertainties, including
those detailed in the Company’s filings with the Securities and Exchange
Commission. Actual results, including, without limitation, actual sales results,
if any, or the application of funds, may differ from those set forth in the
forward-looking statements. These forward-looking statements involve certain
risks and uncertainties that are subject to change based on various factors
(many of which are beyond the Company’s control). The Company undertakes no
obligation to publicly update forward-looking statements, whether because of new
information, future events or otherwise, except as required by law.
###
Page 2 of
2